Research ExplorerPublicationsThe immunopeptidomic landscape of ovarian carcinomas

The immunopeptidomic landscape of ovarian carcinomas

Standard

The immunopeptidomic landscape of ovarian carcinomas. / Schuster, Heiko; Peper, Janet K; Bösmüller, Hans-Christian; Röhle, Kevin; Backert, Linus; Bilich, Tatjana; Ney, Britta; Löffler, Markus W; Kowalewski, Daniel J; Trautwein, Nico; Rabsteyn, Armin; Engler, Tobias; Braun, Sabine; Haen, Sebastian P; Walz, Juliane S; Schmid-Horch, Barbara; Brucker, Sara Y; Wallwiener, Diethelm; Kohlbacher, Oliver; Fend, Falko; Rammensee, Hans-Georg; Stevanović, Stefan; Staebler, Annette; Wagner, Philipp.

In: P NATL ACAD SCI USA, Vol. 114, No. 46, 14.11.2017, p. E9942-E9951.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schuster, H, Peper, JK, Bösmüller, H-C, Röhle, K, Backert, L, Bilich, T, Ney, B, Löffler, MW, Kowalewski, DJ, Trautwein, N, Rabsteyn, A, Engler, T, Braun, S, Haen, SP, Walz, JS, Schmid-Horch, B, Brucker, SY, Wallwiener, D, Kohlbacher, O, Fend, F, Rammensee, H-G, Stevanović, S, Staebler, A & Wagner, P 2017, 'The immunopeptidomic landscape of ovarian carcinomas', P NATL ACAD SCI USA, vol. 114, no. 46, pp. E9942-E9951. https://doi.org/10.1073/pnas.1707658114

APA

Schuster, H., Peper, J. K., Bösmüller, H-C., Röhle, K., Backert, L., Bilich, T., Ney, B., Löffler, M. W., Kowalewski, D. J., Trautwein, N., Rabsteyn, A., Engler, T., Braun, S., Haen, S. P., Walz, J. S., Schmid-Horch, B., Brucker, S. Y., Wallwiener, D., Kohlbacher, O., ... Wagner, P. (2017). The immunopeptidomic landscape of ovarian carcinomas. P NATL ACAD SCI USA, 114(46), E9942-E9951. https://doi.org/10.1073/pnas.1707658114

Vancouver

Schuster H, Peper JK, Bösmüller H-C, Röhle K, Backert L, Bilich T et al. The immunopeptidomic landscape of ovarian carcinomas. P NATL ACAD SCI USA. 2017 Nov 14;114(46):E9942-E9951. https://doi.org/10.1073/pnas.1707658114

Bibtex

@article{57ffec356bab44fdbdc527520f6b5986,
title = "The immunopeptidomic landscape of ovarian carcinomas",
abstract = "Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a variety of benign sources has unveiled a multitude of ovarian cancer antigens (MUC16, MSLN, LGALS1, IDO1, KLK10) to be presented by HLA class I and class II molecules exclusively on ovarian cancer cells. Most strikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in EOC, are prominent in a majority of patients. Differential gene-expression analysis has allowed us to confirm the relevance of these targets for EOC and further provided important insights into the relationship between gene transcript levels and HLA ligand presentation.",
keywords = "Antigen Presentation/immunology, CA-125 Antigen/immunology, Carcinoma, Ovarian Epithelial, Female, GPI-Linked Proteins/immunology, Galectin 1/immunology, Gene Expression Regulation, Neoplastic, HLA-DR Antigens/immunology, Histocompatibility Antigens Class I/immunology, Histocompatibility Antigens Class II/immunology, Humans, Immunotherapy, Indoleamine-Pyrrole 2,3,-Dioxygenase/immunology, Kallikreins/immunology, Ligands, Membrane Glycoproteins/analysis, Membrane Proteins/immunology, Neoplasms, Glandular and Epithelial/immunology, Ovarian Neoplasms/immunology, Vaccination",
author = "Heiko Schuster and Peper, {Janet K} and Hans-Christian B{\"o}sm{\"u}ller and Kevin R{\"o}hle and Linus Backert and Tatjana Bilich and Britta Ney and L{\"o}ffler, {Markus W} and Kowalewski, {Daniel J} and Nico Trautwein and Armin Rabsteyn and Tobias Engler and Sabine Braun and Haen, {Sebastian P} and Walz, {Juliane S} and Barbara Schmid-Horch and Brucker, {Sara Y} and Diethelm Wallwiener and Oliver Kohlbacher and Falko Fend and Hans-Georg Rammensee and Stefan Stevanovi{\'c} and Annette Staebler and Philipp Wagner",
note = "Copyright {\textcopyright} 2017 the Author(s). Published by PNAS.",
year = "2017",
month = nov,
day = "14",
doi = "10.1073/pnas.1707658114",
language = "English",
volume = "114",
pages = "E9942--E9951",
journal = "P NATL ACAD SCI USA",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "46",

}

RIS

TY - JOUR

T1 - The immunopeptidomic landscape of ovarian carcinomas

AU - Schuster, Heiko

AU - Peper, Janet K

AU - Bösmüller, Hans-Christian

AU - Röhle, Kevin

AU - Backert, Linus

AU - Bilich, Tatjana

AU - Ney, Britta

AU - Löffler, Markus W

AU - Kowalewski, Daniel J

AU - Trautwein, Nico

AU - Rabsteyn, Armin

AU - Engler, Tobias

AU - Braun, Sabine

AU - Haen, Sebastian P

AU - Walz, Juliane S

AU - Schmid-Horch, Barbara

AU - Brucker, Sara Y

AU - Wallwiener, Diethelm

AU - Kohlbacher, Oliver

AU - Fend, Falko

AU - Rammensee, Hans-Georg

AU - Stevanović, Stefan

AU - Staebler, Annette

AU - Wagner, Philipp

N1 - Copyright © 2017 the Author(s). Published by PNAS.

PY - 2017/11/14

Y1 - 2017/11/14

N2 - Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a variety of benign sources has unveiled a multitude of ovarian cancer antigens (MUC16, MSLN, LGALS1, IDO1, KLK10) to be presented by HLA class I and class II molecules exclusively on ovarian cancer cells. Most strikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in EOC, are prominent in a majority of patients. Differential gene-expression analysis has allowed us to confirm the relevance of these targets for EOC and further provided important insights into the relationship between gene transcript levels and HLA ligand presentation.

AB - Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a variety of benign sources has unveiled a multitude of ovarian cancer antigens (MUC16, MSLN, LGALS1, IDO1, KLK10) to be presented by HLA class I and class II molecules exclusively on ovarian cancer cells. Most strikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in EOC, are prominent in a majority of patients. Differential gene-expression analysis has allowed us to confirm the relevance of these targets for EOC and further provided important insights into the relationship between gene transcript levels and HLA ligand presentation.

KW - Antigen Presentation/immunology

KW - CA-125 Antigen/immunology

KW - Carcinoma, Ovarian Epithelial

KW - Female

KW - GPI-Linked Proteins/immunology

KW - Galectin 1/immunology

KW - Gene Expression Regulation, Neoplastic

KW - HLA-DR Antigens/immunology

KW - Histocompatibility Antigens Class I/immunology

KW - Histocompatibility Antigens Class II/immunology

KW - Humans

KW - Immunotherapy

KW - Indoleamine-Pyrrole 2,3,-Dioxygenase/immunology

KW - Kallikreins/immunology

KW - Ligands

KW - Membrane Glycoproteins/analysis

KW - Membrane Proteins/immunology

KW - Neoplasms, Glandular and Epithelial/immunology

KW - Ovarian Neoplasms/immunology

KW - Vaccination

U2 - 10.1073/pnas.1707658114

DO - 10.1073/pnas.1707658114

M3 - SCORING: Journal article

C2 - 29093164

VL - 114

SP - E9942-E9951

JO - P NATL ACAD SCI USA

JF - P NATL ACAD SCI USA

SN - 0027-8424

IS - 46

ER -